Kolon Life Science said on the 27th that it held a shareholders' meeting and a board meeting on the 26th and appointed Vice President Lee Hanguk as CEO.
Born in 1973, the new CEO, Lee Hanguk, is an expert in the pharmaceutical and biotech industry who has covered the full cycle of new drug, generic, and active pharmaceutical ingredient development and commercialization, from research and development (R&D) to manufacturing, regulatory approvals, and domestic and overseas business development.
Lee graduated from the department of chemistry at Yonsei University and its graduate school. After handling synthetic research, overseas regulatory approvals, overseas business, and the establishment of overseas research hubs at Daewoong Pharmaceutical, Lee served as an executive in the RA institutional sector at a biotech corporations in San Diego, United States.
Lee then moved to Gunil Pharmaceutical, where, after serving in the medical division and the R&D division, Lee served as CEO and maximized profitability and business performance by expanding overseas business and securing manufacturing capabilities for overseas expansion.
Kolon Life Science said it appointed the new CEO, Lee Hanguk, as a specialist who can execute regulatory strategies in the global market and organically connect development, manufacturing, approvals, and commercialization.
New Kolon Life Science CEO Lee Hanguk said, "Based on Kolon Life Science's strong bio and chemical capabilities, we will build new trust in the global bio market and deliver visible results."
Kolon Life Science plans to advance results in the bio institutional sector centered on key gene therapy pipelines such as KLS-3021 and KLS-2031, and to upgrade its two-track growth strategy by expanding supplies of precision chemical materials and active pharmaceutical ingredients in the chemical institutional sector and refining its electronic materials portfolio.